Oncoinvent ASA: Grant of share options - mandatory notification of trade

Oslo, Norway, 22 December 2025: Oncoinvent ASA ("Oncoinvent" or the "Company") (OSE: ONCOIN), a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announce that the Board of Directors has granted options to employees. As previously communicated and with the objective of aligning share option participants' interests with those of the shareholders of the Combined Company, the Board of Directors has established a replacement share option and RSU program for employees and board members similar to Oncoinvent's program before the merger with BerGenBio. This has been transformed by using the exchange ratio in the merger and adjusting the strike to secure a value neutral transition. Following this, a total of 6,355,096 share options has been granted as replacement for the previous option program, of which 4,451,133 to primary insiders. See the attached forms. Options granted under the share option program will normally vest equally over a four-year period from the date of grant and each option, when exercised, will give the right to receive one share in the Company at a fixed strike price set at time of grant. Options granted under the share option program expire seven years after grant date. In addition, a total of 25,770,000 new share options were granted, equal to 5.4% of fully diluted shares in the Company. Total options outstanding after this grant are 32,125,096, equal to 6.7% of fully diluted shares in the Company. The strike price for this grant is NOK 0.50 per option equal to the volume weighted average share price the last day before the grant, limited to nominal value of the shares. Of the total grant, 15,500,000 share options were granted to primary insiders of the Company (total holdings of share options following this grant and replacement program): Øystein Soug - CEO: 5,000,000 (6,106,466) Kari Myren - CMO: 2,000,000 (2,358,399) Anne-Kirsti Aksnes - CCO: 2,000,000 (2,336,751) Gro Hjellum - COO: 2,000,000 (2,334,826) Kristine Lofthus - CPO: 1,500,000 (1,829,534) Stian Brekke - Head of RA:  1,500,000 (1,828,813) Anne Cecilie Alvik - Head of QA: 1,500,000 (1,828,452) Share options issued to the board as part of the replacement option program following the merger: Gillies O'Bryan-Tear (Chairperson of the Board): 353,722 Kari Grønås (Board member): 165,168 Hilde Steineger (Board member): 165,168 Orlando Oliveira (Board member): 165,168 Johan Häggblad (Board member): 95,012 The board considers an option program as an important element in attracting and retaining employees to foster long-term success. The board considers the option program terms and allocation to be at the market for comparable peers. PDMR notifications of transactions: replacement options (https://mb.cision.com/Public/15728/4285903/8cd75ccb730cd061.pdf) PDMR notifications of transactions: new grants (https://mb.cision.com/Public/15728/4285903/81db31dd23e60ae6.pdf) This information is subject to the disclosure requirements pursuant to article 19 of the regulation EU 596/2014 (the EU Market Abise Regulation) and section 5 -12 of the Norwegian Securities Trading Act. For further information, please contact: Oystein Soug, Chief Executive Officer Email: soug@oncoinvent.com About Oncoinvent Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical development program in two indications. One Phase 1 trial and one Phase 1/2a trial have been completed and one randomized Phase 2 trial is currently ongoing in the US, UK and Europe. Early clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. The Oncoinvent team consists of approx. 40 employees and runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Oslo Stock Exchange. About Radspherin Radspherin® is an investigational radiopharmaceutical designed for the local treatment of cancer that has spread to body cavities. It consists of calcium carbonate microparticles containing the radioactive material radium-224. The mode of action is the decay of radium-224 emitting alpha-particles, a highly potent form of ionizing radiation. Radspherin® is investigated in clinical studies to treat peritoneal carcinomatoses from ovarian and colorectal cancer and it is administered intraperitoneally after surgical resection with removal of all macroscopic tumors. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Oncoinvent's plans, estimates, or expectations will be achieved. These forward -looking statements represent Oncoinvent's expectations as of the date of this press release, and Oncoinvent disclaims any obligation to update the forward -looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers.